KRAS and non-small cell lung carcinoma: TR102 (stage IIB, adenocarcinoma, 55-year-old male with occupation risk, smoker) has a KRAS missense mutation c.35G>T characterized as pathogenic with moderate impact on protein function and reported in non-small cell lung carcinoma.